From Patient Registry to a International Scientific Conference
Our study on NF1-associated gastrointestinal stromal tumors was accepted for presentation at ASCO this year - this milestones highlights the power of patient registries.
LRG & Collaborators Publish New Paper on Adjuvant Imatinib in KIT Exon 9 Mutations
Published on February 26, 2026, this international study represents a major collaboration between The Life Raft Group and thirty-five leading cancer centers across the U.S., Europe, and Japan to better understand treatment for gastrointestinal stromal tumors (GIST) with KIT exon 9 mutations.
Patient Perspective on Testing – Survey Highlights
Survey highlights show that most GIST patients receive mutational testing, but awareness of ctDNA testing remains low despite strong interest.
ctDNA and the INSIGHT Study
Dr. Jonathan Trent and Denisse Evans will share how ctDNA can help monitor GIST and guide personalized treatment.
New Collaborative Study on Genomic Testing in SDH‐Deficienct GIST
The LRG and the Pediatric & SDH-Deficient GIST Consortium published a paper this February on Genomic Testing in SDH-deficient GIST.
ESMO 2024 Summary
ESMO 2024 Summary
The Life Raft Group’s ASCO Educational Book Manuscript Published
The Life Raft Group is proud to share our ASCO Educational Book Manuscript - “Leveraging Patient Engagement Through Collaboration for Improved Global Health Outcomes in Sarcoma”
New Life Raft Group Paper Published
The LRG publishes, "Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry" Cancer Investigation ,Vol. 41, 2023. Issue 5 [...]
The Importance of Data for Research – The LRG GIST Patient Registry
In this installment of Fueling GIST Research, our Data Management & Research team shares about their management & curation of the LRG GIST Patient Registry which informs patient direction, clinical trials, and research studies.